​​許多完全接種了covid疫苗的人現在都失明了 我們聽說了很多關於注射後心肌炎和心包炎的案例，以及接受者即使在註射後仍反複檢測出病毒“陽性”。但是，武漢冠狀病毒（COVID-19）的“完全接種疫苗”中還有另一個很少被提及的副作用：失明。 英國的最新數據表明，越來越多的人正在失去視力。藥品和保健品監管機構 (MHRA) 黃卡系統目前顯示，在被輝瑞-BioNTech 針刺傷的人群中，有 163 例完全失明，另外還有 6 例中心視力喪失和 4 例突然視力喪失。 據報導，現在還有 21 人患有由輝瑞注射液特別引起的“暫時性失明”。這種不良反應包括一次視覺障礙或一隻眼睛失明幾秒鐘甚至幾分鐘。 據報導，除此之外還有 20 人患有稱為“單側失明”的反應，即一個人僅一隻眼睛失明或視力模糊。 “截至 2022 年 4 月 6 日，總共有 8,016 例眼部疾病被報告為對輝瑞 (Pfizer) 疫苗的不良反應，”《每日曝光》報導。 僅僅為了感覺“受到保護”免於感冒而失明是否值得？ 阿斯利康（AstraZeneca）注射劑是目前英國可用的 COVID 刺針之一，它也與失明病例有關。 截至 4 月 6 日，MHRA 已收到 324 例失明報告，3 例中心視力喪失報告，5 例突發視力喪失報告，以及 14,895 例眼部疾病中的 29 例短暫失明報告，所有這些都與阿斯利康針頭有關。 Moderna 還在英國對人們進行了​​刺激，儘管速度比上述公司小得多。儘管如此，許多服用 Moderna 針的人現在也失明了。 MHRA 顯示，與 Moderna 注射劑一起，已有 34 例失明報告和 56 例視力障礙報告。總共有 1,519 例眼部疾病被報告為對 Moderna 刺拳的不良反應。 “總的來說，當包括未指定疫苗品牌的不良反應時，有 24,516 種眼部疾病報告為對 Covid-19 注射劑的不良反應，其中 525 種反應是完全失明，”Expose 報導。 “‘事實核查人員’與當局一道，一直在調查這些數據，並將其標記為不可靠。他們的理由是，‘僅僅因為有人在接種疫苗後報告了這一事件，並不一定意味著它是由於疫苗造成的。’” 一位名叫路易斯的人在推特上記錄了他妻子的故事，她在接受阿斯利康 (AstraZeneca) 刺戳後的幾周和幾個月內，左眼完全失明，右眼失明 30-60%。 治療這名婦女的神經科醫生警告她不要注射第二劑。 “正如你所看到的那樣，事實核查人員無視‘不一定是疫苗的錯’而忽視的痛苦，對於報告他們的人來說是非常真實的，”Exposé 補充道。 “但為什麼 COVID 疫苗會導致人們失明呢？” 答案可能與 COVID 疫苗也會引起包括中風在內的主要心血管問題有關。視力喪失通常伴隨著中風，所以這一切都開始變得有意義了。 加入並分享👉@NaturalNewsMedia ​​Many people fully vaccinated for covid are now going BLIND We have heard all about the many cases of myocarditis and pericarditis post-injection, as well as recipients repeatedly testing “positive” for the virus even after doing the deed. But there is another concerning side effect occurring in the “fully vaccinated” for the Wuhan coronavirus (COVID-19) that is rarely mentioned: blindness. The latest data out of the United Kingdom suggests that a growing number of fully jabbed people are losing their eyesight. The Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card system currently shows 163 cases of total blindness among people who got jabbed with the Pfizer-BioNTech needle, along with an additional six cases of central vision loss and four cases of sudden visual loss. Twenty-one people also reportedly now suffer from “blindness transient” specifically caused by the Pfizer injection. This adverse reaction involves visual disturbance or loss of sight in one eye for a few seconds or even minutes at a time. Another 20 people beyond that are reported to have suffered from a reaction called “unilateral blindness,” which is when a person got blind or blurred vision in just one eye. “In total, there have been 8,016 eye disorders reported as adverse reactions to the Pfizer jab as of 6th April 2022,” reported the Daily Exposé. Is it worth possibly going blind just to feel “protected” against a cold? The AstraZeneca injection, which is one of the COVID jabs currently available in the U.K., is also linked to cases of blindness. As of April 6, the MHRA has received 324 reports of blindness, three reports of central vision loss, five reports of sudden visual loss, and 29 reports of blindness transient among 14,895 eye disorders, all specifically linked to the AstraZeneca needle. Moderna also jabs people in the UK, though at a much smaller rate than the aforementioned companies. Still, many people who take the Moderna needle are now blind as well. The MHRA shows that in conjunction with the Moderna injection, there have been 34 reports of blindness and 56 reports of visual impairment. In total, there have been 1,519 eye disorders reported as adverse reactions to the Moderna jab. “In all, when including adverse reactions reported where the brand of vaccine was not specified, there have been 24,516 eye disorders reported as adverse reactions to the Covid-19 injections, with 525 of these reactions being complete blindness,” the Exposé reported. “‘Fact-checkers’ alongside authorities have been on the case to sweep this data under the carpet and have labelled it as unreliable. Their reasoning is that ‘just because someone reports the event after having the vaccine, it doesn’t necessarily mean it is due to the vaccine.'” One person who goes by the name of Louis documented on Twitter the story of his wife, who in the weeks and months following her AstraZeneca jab went completely blind in her left eye and between 30-60 percent blind in her right eye. The neurologist who treated the woman warned her not to get the second dose of the shot. “As you can see the misery which the fact checkers are disregarding as ‘not necessarily the fault of the vaccine’ is very real for the people who are reporting them,” the Exposé added. “But why are the COVID vaccines causing people to go blind?” The answer could have to do with the fact that COVID vaccines also cause major cardiovascular problems, including stroke. Visual loss often accompanies stroke, so it is all starting to make sense. Join and share 👉@NaturalNewsMedia

#《莫德納兩劑間隔不得超過42天》 #這是美國疾管中心CDC的說明（www.cdc.gov) 牙醫領導的指揮中心突然宣布：二類人群莫德納第二劑需間隔10至12周，也就是70至84天。這不符合美國疾管中心的6周（42天）限制。 已施打第一劑的朋友，還能「順時中」等過了效期嗎？ ***US CDC原文見CDC官網截圖。 第二劑的時機 第一次和第二次注射之間的時間間隔取決於您接種的疫苗。 如果您接種了 Pfizer-BioNTech COVID-19 疫苗，您應該在第一次注射後 3 週（或 21 天）接種第二針。 如果您接種了 Moderna COVID-19 疫苗，您應該在第一次接種後 4 週（或 28 天）接種第二針。 您應該 盡可能接近推薦的 3 週或 4 週間隔進行第二次注射。但是，如有必要，您可以在第一劑後最多6 週（42 天）內給予第二劑。您不應過早服用第二劑。目前關於早於建議時間或晚於第一次注射後 6 週接受第二次注射的有效性的信息有限。 但是，如果您確實比建議的時間早或晚接種了第二針 COVID-19 疫苗，則不必重新啟動疫苗系列。隨著更多信息的出現，本指南可能會更新。(美國疾管局網站翻譯軟體翻)

以下說的有統計數據嗎? 還是想當然耳? ………… 這兒要提醒大家的是，即使接種了兩劑的疫苗后，人們也可能會被感染。 =================== ▪️第二劑應在第一劑疫苗后 21/28 天接種。 ▪️疫苗進入人體后立即開始形成抗體。 ▪️當我們體內在形成抗體的時期，我們的免疫力會大大降低。 ▪️而我們在 21/28 天內接種第二劑疫苗辰，我們的免疫力會降低更多。 ▪️當第二次注射的 14 天后，抗體在我們體內完全形成時，我們的免疫力開始迅速增長。 ▪️在這一個半月中，由於免疫力降低，病毒進入我們體內的機會非常高。 正是由於在這個脆弱的時間接觸到病毒，人們才會被感染。 ▪️這意味著在這一個半月內出外是非常危險的。 ▪️即使接種了兩劑疫苗后，您也可能成為 Corona 的受害者。 ▪️一個半月后，體內的免疫力提高了 100 到 200 倍，在此之后您就安全了。 ▪️從首次接種疫苗開始，這一個半月要注意安全。 這就是為什麼 ▪️確保戴口罩。 ▪️僅在必要時才出門。 請閱讀 👆🏽，特別是在您要輪到接種疫苗的時候！！！ It is worth knowing the reason for people getting infected even after taking two doses of the corona vaccine. =================== ▪️ The second dose is to be taken 21/28 days after the first dose of the corona vaccine. ▪️ The vaccine starts to form antibodies immediately after entering the body. ▪️ When antibodies are forming in our body, our immunity decreases a lot. ▪️ When we take the second dose of the vaccine after the 21/28 days, our immunity decreases even more. ▪️ 14 days after the second dose, when the antibodies are completely formed in our body, our immunity starts to grow rapidly. ▪️ During this one and a half month, due to low immunity, the chances of the corona virus entering our body are very high. It is due to an exposure to the virus at this vulnerable time that a person gets infected. ▪️ Which makes it very risky to get out of the house during this one and a half months. ▪️ Even after taking two doses of the vaccine, you can become a victim of Corona. ▪️ After one and a half months, the immunity in the body rises by 100 to 200 times, after which you are safe. ▪️ Need to be careful and safe for one and a half months from the first dose. That's why ▪️ Make sure to wear a mask ▪️ Get out of the house only if necessary. Do read 👆🏽if it’s your turn to take that shot ...!

Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions. June 30, 202110:11 AM CSTLast Updated 2 months ago Healthcare & Pharmaceuticals U.S. Commerce chief says Taiwan's TSMC asked for help getting COVID vaccines Reuters 3 minute read U.S. Secretary of Commerce Gina Raimondo takes a question during a press briefing at the White House in Washington, U.S., April 7, 2021. REUTERS/Kevin Lamarque/File Photo The logo of Taiwan Semiconductor Manufacturing Co (TSMC) is pictured at its headquarters, in Hsinchu, Taiwan, Jan. 19, 2021. REUTERS/Ann Wang/File Photo U.S. Secretary of Commerce Gina Raimondo takes a question during a press briefing at the White House in Washington, U.S., April 7, 2021. REUTERS/Kevin Lamarque/File Photo 1/2 The logo of Taiwan Semiconductor Manufacturing Co (TSMC) is pictured at its headquarters, in Hsinchu, Taiwan, Jan. 19, 2021. REUTERS/Ann Wang/File Photo WASHINGTON, June 29 (Reuters) - U.S. Commerce Secretary Gina Raimondo on Monday said she had spoken with the chief executive of Taiwan Semiconductor Manufacturing Co Ltd (2330.TW) (TSMC) and that he had asked for help getting access to COVID-19 vaccines. Raimondo told Reuters in an interview "he asked for help in that regard, he has spoken to high level officials in the White House. We have responded and we definitely want to be a good partner and I do think it's helping." Taiwan said two weeks ago it will allow officials from Taiwan's Foxconn and TSMC to negotiate on its behalf for COVID-19 vaccines. read more Mid-June the United States shipped 2.5 million COVID-19 vaccine doses to Taiwan, more than tripling Washington's previous allocation of shots for the island. read more TSMC said in a statement to Reuters that they believed "getting vaccines for Taiwan would help to protect the communities and ensure normal operations." Taiwan has been trying to speed up the arrival of the millions of vaccines it has on order as it deals with a rise in domestic cases, although infections remain comparatively low. The request from TSMC, the world's biggest manufacturer of semiconductors on contract, coincides with a global chip shortage that has slowed production of manufacturers around the world, including in the U.S. auto industry where it is forecast the crisis will hit the production of 3.9 million vehicles. Raimondo has a key role in resolving the crisis for U.S. companies. Although there has been no major impact so far on chip production in Taiwan since domestic cases began rising in the middle of May, some U.S. auto executives have told Reuters privately earlier this month they were concerned COVID-19 in Taiwan could impact the flow of semiconductors to U.S. factories. Reporting by David Shepardson in Washington; Additional reporting by Ben Blanchard in Taipei; Editing by Simon Cameron-Moore Our Standards: The Thomson Reuters Trust Principles. More from Reuters Credit Suisse to U.S. staff: get shot, or go home Credit Suisse to U.S. staff: get shot, or go home Credit Suisse to U.S. staff: get shot, or go home German business morale dips on new health worries German business morale dips on new health worries Xiaomi sees revenue surge, eyes EV-market debut Xiaomi sees revenue surge, eyes EV-market debut Toshiba reviewing new strategic ideas - sources Toshiba reviewing new strategic ideas - sources J&J says booster shot vastly increases antibdody J&J says booster shot vastly increases antibdody Qantas aims for international travel in December Qantas aims for international travel in December Air NZ suspends outlook as borders stay shut Air NZ suspends outlook as borders stay shut Japan suspends 1.6 mln doses of Moderna shot Japan suspends 1.6 mln doses of Moderna shot Shakes off menu at UK McDonald's as milk runs dry Shakes off menu at UK McDonald's as milk runs dry Legal Lookahead: Purdue Pharma makes final push to exit bankruptcy Legal Lookahead: Purdue Pharma makes final push to... Read Next United States Illinois Governor to order statewide mask mandate and order masks and vaccines for schools - media 7:55 PM CST Europe EU says COVID boosters may have higher legal risks without EMA approval 7:34 PM CST World Qatar offering COVID vaccines to Afghanistan evacuees yet to transit 7:29 PM CST Americas Brazil's Eurofarma to make Pfizer COVID-19 shots in Latin America 7:10 PM CST Sign up for our newsletter Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox. Healthcare & Pharmaceuticals Healthcare & Pharmaceuticals · 8:04 PM CST Illinois governor to announce mask mandate, order vaccines for schools - reports Illinois Governor J.B. Pritzker is expected to announce a new COVID-19 policy for the state on Thursday, requiring eligible students and school staffers to be vaccinated and to wear masks in schools and colleges, the Chicago Tribune and other media reported. Healthcare & Pharmaceuticals EU says COVID boosters may have higher legal risks without EMA approval 7:34 PM CST Healthcare & Pharmaceuticals Japan suspends 1.6 mln doses of Moderna shot after contamination reports 8:05 PM CST Healthcare & Pharmaceuticals Sydney hospitals erect emergency tents as COVID-19 cases hit record 12:32 PM CST Healthcare & Pharmaceuticals New Zealand's Ardern says lockdown working to limit Delta spread 3:10 PM CST Latest Home Media Videos Pictures Graphics Browse World Business Legal Markets Breakingviews Technology Investigations Lifestyle About Reuters About Reuters Careers Reuters News Agency Brand Attribution Guidelines Reuters Leadership Reuters Fact Check Reuters Diversity Report Stay Informed Download the App Newsletters Information you can trust Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers. Follow Us Thomson Reuters Products Westlaw Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology. Onesource The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs. Checkpoint The industry leader for online information for tax, accounting and finance professionals. Refinitiv Products Eikon Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface. Refinitiv Data Platform Access to real-time, reference, and non-real time data in the cloud to power your enterprise. World-Check Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks. Advertise With Us Advertising Guidelines Cookies Terms of Use Privacy Corrections Site Feedback All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2021 Reuters. All rights reserved

轉分享： 這是中研院生醫所所長郭沛恩院士 (他也是UCSF 教授）寫給前副總統陳健仁及時中部長，関於目前COVID-19 的一些建議，希望政府能夠接納。 Dear VP Chen, Hope that things are going well. I just completed my 9th quarantine after my 9th trip to Taipei during the pandemic and see that the Omicron variant of COVID-19 is now firmly established in Taiwan. While the CECC is moving quickly to address the widening spread of COVID-Omicron and is heading in the right direction, I find that the current policy is unsustainable and the messaging can be much improved. Since I was told that the CECC would welcome my suggestions, I have decided to do so. Please forward this message to the CECC for their consideration. 1. It is now very clear that COVID-Omicron is a very different disease than COVID-ALPHA/BETA/DELTA. Current vaccines are developed from COVID-ALPHA and cannot prevent INFECTION by COVID-Omicron even though they lower significantly the risk of SEVERE DISEASE and DEATH for those who are fully vaccinated and received booster shots recently. In addition, COVID-Omicron is highly contagious and has a very short incubation time; but it causes a milder disease, including shortened disease course and contagious period. 2. Because of the above, contact tracing does not work and avoiding infection is futile except one is in strict isolation or wears a PROPERLY FITTED N95 mask around others (see a very nice article about this in the NYT attached). This means that COVID testing in asymptomatic people is a waste of resources and is justified only in a limited set of situations (such as someone who works closely with vulnerable populations - e.g., nursing home and hospital workers - who has been in close contact with a positive case and needs to test negative to return to work). 3. Although the rate of hospitalization and death due to COVID-Omicron is low, when large populations are infected, the number of severe cases and severe disease is still significant (0.4% of 23 million people hospitalized = 92,000 in the hospital; 0.04% of 23 million people can die = 9,200 deaths) so the key is to keep the vulnerable people from developing severe disease. Medications used for COVID-ALPHA/BETA/DELTA variants such as antibody treatments and Remdesivir, etc., do not work for COVID-Omicron but the oral antivirals from Pfizer and Merck work amazingly well for preventing death (>85% reduction) and hospitalization. Paxlovid has done better in clinical trials to prevent hospitalization but it has many drug-drug interactions so many elderly people cannot use it. Molnupiravir has the theoretical risk of mutagenesis in pregnant women but for the elderly who are past reproductive age, it is a very safe and effective drug to use. I encourage the CECC to contact their counterparts in Japan, Singapore, Israel and the UK to get their experience in using these two oral anti-virals in the recent COVID-Omicron surge. [Full Disclosure: Dr. Dean Li, President of Merck Research Laboratories, is my brother-in-law so I am not pushing the Merck pill for obvious conflict of interest reasons.] Based on the above, my suggestions on messaging are: 1. Tell the country that COVID-Omicron is an entirely different disease than the previous COVID variants so the whole country IS NOT IMMUNE to getting the infection. However, through the sacrifice and cooperation of everyone in Taiwan, the country succeeded in preventing disease and death during the previous waves of infection that caused a lot of problems around the world. This is shared success that the CECC and everyone in Taiwan should take credit, be proud of, and very relieved by. 2. Despite the fact that no one is protected from infection, but because COVID-Omicron is mild, public health policy needs to be adjusted to focus on treating the vulnerable rather than preventing infection of all. 3. Acknowledge that some segments of society have been severely affected by COVID policies so the recovery of these sectors is taken in consideration in updating the public health policy. 4. Acknowledge that some COVID policies were confusing to the public in the past so the new policies will be more consistent and logical. For example, the policy of requiring masking outdoors while people eating at restaurants indoors are not required to mask makes no sense. My suggestions for the new policy are geared towards lowering hospitalization and death rates while avoiding unnecessary disruptions in people's lives: 1. Push vaccination for vulnerable groups (the elderly and those with pre-existing conditions that make them more prone to severe disease). Send vaccination nurses to the nursing homes and neighborhoods with elderly people to get everyone fully vaccinated (including booster shots). Getting the 30% of those 65-75 and 44% of elderly >75 who have not been fully vaccinated and boosted should be a high priority 2. Use the "test positive and treat" strategy for those in vulnerable groups. As I mentioned before, Paxlovid for all but Molnupiravir for those who cannot take Paxlovid. Treat them before their symptoms get worse because it is cheaper to give them the medicine than risk their need for hospitalization. 3. No more putting those with mild disease in special facilities or hospitals so that there are plenty of capacity for those who need hospitalization. 4. Recommend (not mandate with threat of punishment) those who have close contact with COVID-Omicron patients to mask around others for 5 days (no need to do so with household members because they are already given it to them) if they are asymptomatic. 5. No testing of asymptomatic people unless their job requires it (nursing home, hospital, etc.). 6. No more closing schools, factories, or offices because of positive COVID-Omicron cases. 7. No more mandatory masking except for those described in #4 above. People here are so used to masking that many will still do so with the threat of punishment. 8. No more mandatory quarantine, even for those who test positive. Highly recommend those who test positive to wear a mask when around people and not eat with others but not make it a punishable offense. [Treat them like people who have a bad flu, not like criminals.] 9. No more testing or quarantine requirements for visitors from abroad. As the local infection rate is now higher than that many other countries, there is no reason to require new arrivals to do anything different when they are asymptomatic. It's confusing to many that I can go anywhere in the world without quarantine but have to do quarantine plus multiple tests when arriving in Taiwan (and a handful of Asian countries). The benefit of the policies listed above is that the resources of the country are directed toward saving lives rather than collecting lots of infection data. It will reclaim the international travel hub status of Taoyuan International Airport (and not let Singapore and Seoul dominate the air travel sector) and revive the tourism, convention, airline, hotel businesses. It will simplify everyone's life and reduce anxiety. It may be counter intuitive but if you look at the data from the US university campuses and European countries, it is better to get as many young people infected as quickly as possible to shorten the surge while building up herd immunity for COVID-Omicron without a lot of severe cases. The old policy for flattening the curve is to prevent overwhelming the hospitals but with oral antivirals and milder disease, there is no need to flatten the curve. It is better to get the whole surge completed in 2 months like in most countries that pursue a more open policy. I am convinced that when the messaging is clear and based on current understanding of the situation, the people will embrace it and praise the CECC's leadership. Best, Pui -- Pui-Yan Kwok, MD, PhD Director, Institute of Biomedical Sciences Academia Sinica

疫苗再問～～ 台大黃立民教授回答～～ 1⃣️打了第一針之後，免疫系統記得這1針，不管隔多久再打第2針，效果都會持續。 2⃣️依國外臨床試驗的結果，保護效果： 間隔小於6週是55％ 間隔6～8週是59％ 間隔9～11週是63％ 間隔12週以上是81％ 3⃣️ 不同廠牌新冠疫苗可以混打嗎？ 答：可以，但先後順序很重要，#第1劑打AZ（腺病毒載體疫苗），第2劑可以繼續打AZ或打莫德納或輝瑞/BNT疫苗（mRNA疫苗）； #但第1劑打莫德納或輝瑞/BNT疫苗，第2劑仍須打相同疫苗，#不能打AZ。因為mRNA疫苗第1劑的效果只有50％多，必須靠打第2劑把整個免疫效果拉上來，但AZ的免疫原性沒有mRNA疫苗強，因此第1劑打mRNA疫苗，第2劑一定也要打mRNA疫苗才有效。 4⃣️ 只打1劑有多少保護效果？ 答：依疫苗接種覆蓋率及疫情嚴重程度，保護效果從5～6成到8～9成不等。 依臨床試驗研究，只打1劑的保護效果， AZ是76％， 嬌生是66％， 輝瑞/BNT是52％， 莫德納是65％。 5⃣️ 研究顯示南非變種病毒中的1484K可能大幅影響疫苗效力，那打疫苗還有效嗎？ 答：1484K變異株其實並沒有逃脫疫苗的掌握，對付帶有1484K的變種病毒，在新一代疫苗出來前，可以用儘快施打兩劑提高抗體來因應。 目前看起來1484K會減低疫苗效率約6～8倍左右，如果可以打出非常高量的抗體，比如說打出1,000倍的抗體，除以6還是100多倍，足夠抑制這個病毒。所以目前遇到變種病毒，第一個策略是把抗體打高一點，第二個策略更好，就是做新的疫苗，不過這需要時間。 6⃣️ 疫苗覆蓋率必須達6～7成才能達到群體免疫，台灣解封路遙遙？ 答：當我們疫苗覆蓋率達到3～4成時，疫情會比較好控制。 台大醫院官網： 新冠肺炎Q＆A專區 https://www.ntuh.gov.tw/COVID19-QA/Index.action......

(*)我一直不能理解為何台灣打日本產的124萬劑量AZ疫苗，致死率比世界其他國家高？（截止2101/6/24，政府公布的AZ疫苗施打後不良反應死亡人數高達169人：https://tw.appledaily.com/life/20210624/6LPFJOPW6REC5PFL4DXLRE42ME/） 今天看到這個視頻，這位ERIC追蹤查核，才知道，原來WHO認證緊急授權使用的AZ疫苗，目前只有印度跟韓國生產的AZ疫苗，有通過使用許可。這解釋了為什麼日本掌握1.2億劑的AZ疫苗，卻不在日本施打。 》今日節目 1:43:10 「ERIC同學爆料：日本贈台AZ未取得WHO的認證：https://youtu.be/YMFg90A-FTA By) Km Lam 世衛在聲明中說，世衛今天將兩種版本的AZ疫苗列入緊急使用授權名單，同意全球透過COVAX開始使用這些疫苗。兩種版本是指由印度血清研究所（SII）和韓國SKBio所生產的AZ疫苗。 雖然疫苗是相同的，但每個製程都需個別審查。 （法新社日內瓦15日電）2021年2月16日 獨》日捐台AZ疫苗未列WHO緊急使用名單 莊人祥：非必要條件～2021//06/28/中時 鄭郁蓁 ～ 原來日本AZ不止沒有『原廠授權條款』，連『使用認證』都沒有：https://www.chinatimes.com/realtimenews/20210628004836-263301?utm_source=push&utm_medium=image ）根據洪孟楷提供的資料指出，目前我國採購、COVAX到貨的AZ疫苗皆由韓國生產，第二批COVAX到貨的AZ疫苗是義大利製造，採購來的莫德納疫苗產地則是西班牙，日本供台的AZ疫苗則由日本生產；由此看來，這些疫苗皆非「原廠生產」：民間捐贈需原廠證明 藍委揭目前施打疫苗卻全是「代工生產」（義大利也有生產AZ？可能2月以後通過WHO許可？)：https://udn.com/news/story/6656/5566206 ※資料陳列區： 全球疫苗荒！為什麼日本還給台灣124萬劑AZ疫苗？ https://futurecity.cw.com.tw/article/2047 Japanese drugmaker starts AstraZeneca vaccine production https://www.japantimes.co.jp/news/2021/03/12/national/astrazeneca-vaccine-japan/ AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-covid-19-vaccine-vaxzevria-authorised-for-emergency-use-in-japan.html WHO SUMMARY OF PRODUCT CHARACTERISTICS https://extranet.who.int/pqweb/sites/default/files/documents/smpc-azd1222-en.pdf?fbclid=IwAR2H2TI0YgjNz5QeushVCtayCaWuGNYdiYQIIGK-9ab-LddFCUgmXk0113I WHO Vaccines Guidance document(表格) https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf 日本贈台AZ疫苗首波 新北獲配8.3萬劑最多 https://www.cna.com.tw/news/firstnews/202106120178.aspx 日本贈124萬劑AZ疫苗照曝光！力拚11日驗畢 可望與莫德納一起配發 https://today.line.me/tw/v2/article/VkqXvg 国内製造の新型コロナウイルスワクチンによる国際貢献について https://www.mhlw.go.jp/stf/newpage_19070.html モデルナとアストラゼネカのワクチン 正式承認 厚労省 https://www3.nhk.or.jp/news/html/20210521/k10013043721000.html

《 疫苗快報/8.31.2021： 美國疾管局(CDC)主任承認，打過疫苗的人，隨著時間的增加，感染新冠病毒的狀況正在惡化中…… 》 ___________________________________________________ (筆者註記：下文是英文原版的摘要，英文原版附於中文摘要的下方) 注射新冠疫苗後，已有幾萬、幾十萬的不良反應與猝死事件提報到「美國疫苗不良反應通報系統」(VAERS)。 根據美國CDC的統計，自2020年12月14日至2021年8月13日，提報到「美國疫苗不良反應通報系統」的不良反應共595,700起，其中猝死者共13,068人。［註：不過，這是美國公衛官僚系統竄改真實數據之後，所發佈的大外宣。真相為何呢？ 據哈佛大學去年一項研究，真實數據約為大外宣數據的100倍，另據席連科醫師(Dr. Zelenko)較保守的估計，美國因打了疫苗而猝死的人數應有43萬5,600人之譜－ 平均每月死亡人數多達48,400人。］ CDC主任在最近一次的記者會中被問道，美國疫情惡化的趨勢，一如大家觀察到的以色列的趨勢，是否跟人們打了疫苗後的發生的「抗體依賴的增強效應」(ADE)*有關，他避而不答，顧左右而言他。 ………………………………………………………………………………………… * 人們打了疫苗後發生足以致命的「抗體依賴的增強效應」(ADE)，愈來愈頻見，一如席連科醫師等世界級免疫、傳染病專家先前所預測。讀者諸君，倘你被大藥廠、大媒體詐欺而打了一劑進口疫苗，請勿再被騙打第二次，同時，請務必傾聽專家的良心建議：您得立即每天補充Z-配方保命！【 ●♡ 我們獨家提供國人Dr. Zelenko配方-套組，由 (槲皮素＋維他命C) x 3瓶＋鋅 x 1瓶組成。我們也提供國人專案優惠價5,900元/組－ 節省920元。［註：每天服用本套組內的槲皮素、維他命C三餐後各1粒、礦物質鋅每日1粒，典型足敷3個月使用，適合所有人。打過疫苗者、及糖胖症、心臟病患者、癌症患者尤其需要。］ 】， ————————————————————————————— ( 英文原版/8.30.2021刊出) Tens of thousands of adverse reactions and 的death following COVID shot reported to VAERS, and CDC director admits vaccinated individuals having “worsening infections over time” In a recent press interview, CDC Director Rochelle Walensky admitted that people who have had the COVID shot could experience “worsening infections over time.”  Walensky does not offer any insight into whether this trend, currently observed in countries like Israel, could be related to antibody-dependent enhancement (ADE).  ADE happens when antibodies generated during an immune response to an immunization recognize and bind to a pathogen but cannot prevent infection and could actually increase the severity of symptoms if a person does become infected. Instead, Walensky and other CDC officials use this “worsening infections” trend as a call to get the booster shot into the arms of jabbed people 8 months after their second dose. And yet, reports of adverse health reactions and deaths following COVID shots continue to roll in.  According to the CDC, over 595,700 adverse events have been reported to Vaccine Adverse Event Reporting System (VAERS) since December 14, 2020 (as of August 13, 2021), including 13,068 deaths. There’s no doubt, based on the evidence, this whole situation is going to get much worse before it gets better.  Do your own research and never forget the importance of a nurturing a strong immune system. Sources for this article include: Childrenshealthdefense.org Childrenshealthdefense.org Childrenshealthdefense.org Reuters.com CHOP.edu KHN.org

✍️ 資深媒體人黃清龍關於復星BNT疫苗的十點釋疑 台灣疫情緊急，疫苗採購嚴重落後，大家都很心急。關於是否應該開放復星BNT疫苗進來，這幾天討論得很激烈，許多訊息似是而非，今天我就以一個從事新聞工作36年的老記者，經過多方查證後，不帶偏見﹑沒有黨派地為大家找尋答案﹑釋疑解惑。 　　 一﹑包括南投縣在內的地方政府，已行文中央流行疫情指揮中心，要求同意由縣府購買上海復星醫藥代理的BNT疫苗供民眾施打，地方自主採購疫苗是否可行？ 　　 答案是不行。因為疫苗採購涉及嚴格供貨、冷鏈及嚴謹緊急授權程序，因此必須由中央統籌，並且配合中央整體防疫策略，讓疫苗施打都可以順利進行，符合公平性。蔡總統昨天強調疫苗購買必須由中央統籌，這是正確的。但她又說國際上最好的幾支疫苗，包括英國ＡＺ，美國Moderna（莫德納）及德國ＢＮＴ（輝瑞），台灣都積極接洽採購，也順利訂購到英美兩支疫苗，至於德國的BNT疫苗，台灣也一度幾乎與德國原廠要完成簽約，「因為中國的介入，遲延到現在都無法簽約」。這話就大有商榷餘地。 二﹑復星為什麼能取得大中華區的獨家授權，且不經我方同意就把台灣涵蓋進去？ 解答：復星是在去年三月就和Biontech合作，投入了五千多萬美元，當時Biontech研發的疫苗才剛要開始，並不知道會不會成功，但復星願意賭一把，冒著商業上的投資風險，因此能取得大中華區的授權。一個月後美國輝瑞才跟進，Biontech把歐洲以外市場，分別授權給美國輝瑞和上海復星，復星擁有大中華授權，輝瑞擁有除歐洲和大中華以外的全球授權。因此，台灣要購得BNT疫苗，不可能完全排除復星的角色。 三﹑如果去年11月衛福部同意東洋公司和復星洽購的一千萬劑BNT疫苗，今年第一季台灣就有疫苗進口，是否可減緩這次疫情災難？ 解答：關於東洋代理破局一事，幾個月來出現許多真假難辨的說法，也不必在這裡一一列舉了，不過昨天東洋公司說了，當時未能完成代理，主要是「在價格、數量等內容未能與疾管署取得共識」，以致停擺。據我了解，差別就在買兩百萬劑還是一千萬劑，還有每劑的價格問題。不過客觀地說，當時BNT疫苗還在臨床階段，無法百分之百證實有效，同時間國際上也有多家藥廠的疫苗在研發中，行政院或許事擔心一千萬劑的BNT疫苗若效果不好會挨罵，因此沒有促成此事，也是可以理解的。 往者已矣，但來者可追，即使不去追究去年錯失疫苗的責任，以現在疫苗取得「前不著村﹑後不著店」的情況，政府難道不該從保命優先的角度，開放復星BNT疫苗進口？ 四﹑最近在爭取復星疫苗的都是藍營政治人物，所以這是藍營配合中國對民進黨政府的一場政治鬥爭？ 解答：表面上看似乎是這樣，因為連國民黨主席江啟臣和前高雄市長韓國瑜都出來呼籲了，但實情並非如此。首先，最早與復星洽購BNT疫苗的東洋生技公司，董事長是前行政院長林全，他可不是藍營的人物。再者，今天自由時報也披露了，這一波運作採購復星疫苗最用力的其實是鴻海集團創辦人郭台銘，他原先的構想是由鴻海公司與郭董出資設置的基金會各出資一半，購買一千萬劑的復星BNT疫苗，可無條件捐贈給政府來使用。郭董找上了民進黨黨團總召柯建銘商量，柯建銘從二十三日開始即著手進行努力，包括郭台銘、柯建銘與復星董事長郭廣昌三方，做了多次的討論，這才是這一波為復星疫苗游說的主力，並不是藍營。 五﹑台灣能否與德國的BioNTech直接簽約，不經過復星代理的程序？ 解答：台灣是可以再去找BioNTech談，但BioNTech基於合約，還是會要求台灣來找復星供貨。這是國際授權代理的基本規定，就好像如果有哪家藥品進口商和復星取得代理，台灣任何單位不管是醫院還是企業要洽購疫苗，也是要找這家代理商而不是找復星，道理是一樣的。 至於 蔡總統說找原廠買疫苗，品質才有認證有保障，這就牽涉到復星BNT疫苗的來源是不是有問題。 六﹑復星的疫苗有沒有問題？為什麼中國到現在還沒有核准？ 解答：復星獲德國BioNTech獨家授權的疫苗，一開始和輝瑞一樣都有BNT162b1和BNT162b2兩種，簡稱b1和b2。後來BNT和輝瑞完成一二期試驗後，基於安全性和抗體產生的效果，決定放棄b1，僅以b2繼續完成三期試驗。復星的b1在中國區臨床試驗也在二期卡住無法完成，於是改以b2向中國政府申請藥證。一開始中國政府基於自主權，要求b2三期臨床必須在中國完成，但因確診病例不夠，最後同意可以改成引用全球臨床試驗數據送審，目前正在審核中，最快六月初就會核准。 七﹑復星的疫苗是不是在中國代工的？會不會把香港期限快到的BNT疫苗倒賣給台灣？ 解答：行政院中部辦執行長蔡培慧在臉書發文，指南投縣長林明溱要買的是「中國代工」的復必泰疫苗，把「代理」說成「代工」。有這種說法的不只她，許多名嘴也都這麼說，他們根據不知道從哪裡來的一份復星和BioNTech的合約，還是繁體字的，很奇怪，裡頭說「協議雙方同意在經相關監管機構批准的前提下，根據市場需求情況，分階段推進中國銷售供貨的新冠疫苗產品，包括進口新冠疫苗產品裝灌小瓶的成品以及進口新冠疫苗產品的大包裝製劑，在中國大陸分裝以及在中國大陸生產新冠疫苗產品。」然後就一口咬定復星的疫苗是在大陸代工生產的。 實情是：按照復星和Biontech的合約，前兩億劑BNT疫苗都必須是在德國生產，之後才能在大陸代工生產。由於中國保護自產疫苗，至今尚未核准復星代理的BNT疫苗，如何可能同意它在中國代工生產？目前復星在香港和澳門銷售的復必泰疫苗，都是從德國運來的b2疫苗，和BNT賣給美國、以色列還有德國本地的疫苗完全一樣。至於外傳香港復必泰疫苗打不完，面臨八月中效期過期必須報廢，或者倒賣給台灣，這是假訊息，因香港疫苗根本還不夠，不存在過剩問題。如果台灣進口復星疫苗，當然也是從德國原廠進來，還要重開生產線來生產，沒有所謂效期問題。 八﹑復星現在想賣疫苗給台灣，會不會是想發疫情財？價錢上怎麼樣？ 解答：復星當初投資德國Biontech研發疫苗，出發點是商業而非政治的，龐大投資要回收就得把疫苗賣出去。至今復星只賣出兩百多萬劑給香港和澳門，因為中國大陸沒有核准，所以它確實是有銷售壓力，但現在其實也是台灣向復星買疫苗的好時機，因為有買方議價的優勢。否則等到大陸核准這批疫苗，到時候我們還未必買得到。至於實際的價格，因為涉及商業機密，我們無從得知，但要求一個正常價格應該是做得到的，例如每劑疫苗不能高過莫德納，這絕對可以去談。 九﹑代理BNT疫苗進來，程序怎麼走？需要多少時間？ 解答：台灣藥品進口商如果要向復星代理b2疫苗進來，要先取得1.台灣政府的進口許可，2.台灣政府核准的藥品證明。至於時間多長，就要看彼此洽商的進度，如果能一少些不必要的政治考慮，當然越快越好。 十﹑復星賣疫苗給台灣有沒有政治考慮？為什麼國台辦昨天又再對台叫戰：中國疫苗是要是不要？ 解答：也不能說完全沒有政治考慮，畢竟復星是大陸的企業。但更接近事實的是在商言商。坦白說，這件事如果要促成，國台辦最好少講話，不要插手，讓BioNTech、復星與台灣三方的洽談可以在商言商去完成。但台灣自己也要實事求是，不要老是繞著原廠與代理之間的爭議糾纏，沒完沒了。 兩岸問題脫離不了政治，執政者卻要懂得如何去虛就實。現在疫情緊急，沒有疫苗的話，等到確診每天上千，死亡每天上百，怎麼辦？人命關天，保命要緊，才是眼前最重要的，您說對不對？

台灣人林聰興博士 民國76年台大農化系畢業，赴美深造取得生化博士學位後，一直專注新藥研發，現服務於輝瑞藥廠，2019年輝瑞表揚全公司15位最佳研發人員，他個人及其領導的部門即獲得其中3項，對於研發新藥的貢獻是非常傑出的。 林聰興博士非常關心台灣疫情發展，說了幾個重點，希望能有所幫助： 1.藥效與副作用： 輝瑞mRNA疫苗，防疫效果是最好的，由於輝瑞藥廠經驗豐富，劑量得宜，所以副作用少而小。 依美國經驗及該公司的統計，只要有3成的人打了，疫情就明顯下降，現在打了6成，全美已經解封，完全恢復正常生活了。 現在還在做的是12歲以下兒童的試驗。因為還未完成，所以兒童還沒有開始打疫苗。 原先輝瑞公司對這樣的疫苗研發是沒興趣的，因為不具經濟效益，由於新藥研發的時間基本就是要10年以上，且要耗費巨資，若非此次新冠疫情全球蔓延，就算開發好了，也不知道賣給誰。 這一次由於疫情嚴重，美國政府撥下鉅款補助，解決了經費問題，加上FDA緊急授權，才大幅縮短了認證時效。然而也因此輝瑞藥廠在mRNA疫苗技術上一下子就進步了10年。 莫德納mRNA，效果也是很好，但是劑量的經驗較不足（不如輝瑞的豐富經驗），所以二期試驗時為求有效，劑量標準訂得較重，因此副作用較大、較明顯。 輝瑞疫苗只要一劑就有良好的保護力，加拿大政府已決定，全國先打第一輪一劑，之後再打第二輪第二劑。 2.疫苗採購價格： 輝瑞、莫德納都是商業藥廠，只要其政府開放出口，在商言商，雖有公告牌價，只要有人出高價，就有機會優先獲得。以色列就是出了高價所以最優先。 這次病毒，再度證明猶太人高明的生意人眼光。Pfizer 賣美國政府一個人39 美元(兩劑），以色列出價每人約50美元優先搶得疫苗。有錢能使鬼推磨，台灣要是出價60美元,現在每個人大概都接種了Pfizer或Moderna的疫苗。略通會計的人應該可以算出來封國封城經濟上的損失，遠比出高價買疫苗的錢，不知道要多多少倍。再則全國人為了防疫在精神上的損失和病人生命和健康的損失，是無可估價的。 3.疫苗生產數量： 美國政府說輝瑞年底前可完成30億劑。輝瑞內部估計，年底前可以完成40億劑。 4.疫苗儲存： FDA已核准輝瑞疫苗儲存在一般冰箱4度C，可以保存1個月，若要儲存超過1個月則須-70度C。 5.注射： 由於緊急授權，一般藥局即可注射，不需跑到醫院增加醫院負擔與傳染的危險，讓醫院全力照顧染疫病患。如此可大量快速施打。 6.台灣採購疫苗的費用預估： A.同美國政府採購價：交期到年底 39美元*2300萬*28=251.2億 B.若同以色列：（每人2劑費用） 50美元*2300萬*28=322億 C.就算買貴一點：儘早獲得 60美元*2300萬*28=386.4億 （這比近日行政院宣布：防疫緊急紓困的6千多億，便宜又有效多了） 7.合成技術： mRNA合成理論不難，但是製造卻極難，日本、瑞士也都是製藥強國，也有研發疫苗，但是他們還是優先救人，先跟輝瑞、莫德納買。 8.各國的採購： 美國疫情大幅下降，而且疫苗也已過剩，在美國任何人只要出示證件，就可以免費施打，許多加拿大、墨西哥人就跑到美國去打。 現在美國政府已開放疫苗出口外銷，初期以其相鄰的國家，加拿大、墨西哥優先。 歐盟則已再下單給輝瑞第二輪的9億劑，並且表達再買第三輪的9億劑意願。 台灣政府採購第一批疫苗錯過了先機，現在應該積極洽購第三剤的booster shot以防變異株肆虐。 以色列和歐盟都已簽約。現在台灣若不佈局，到時候又重蹈覆轍，搶不到疫苗。 有管道的同學/朋友/長輩，請跟政府進言。 歐美疫苗，因應緊急狀況，跳過二期臨床試驗，直接做三期試驗。 二期試驗是用來決定劑量。所以這次沒做二期，各公司依經驗選單一個劑量做三期。 Moderna 選的劑量有點過重，所以很多人打了，隔天不能上班，要在家休息。 Pfizer 臨床經驗豐富，選的劑量適中，副作用輕微許多。 研發可以，但不可以假設試驗一定成功，疫苗一定有效，且副作用沒問題。萬一結果不理想，國產疫苗不能用，我們短缺疫苗，怎麼辦？ 在醫藥研究上比台灣先進的許多國家，他們都不敢做這種生命關天的豪睹，先買足証明有效的疫苗，再考慮自產的疫苗。